Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 4/20 | 0.70 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 4/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | FLT4 | P35916 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | FRK | P42685 | 1/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28491336 | 0.86 | SMN1; SMN2 (0.58) | SCN2ASCN10ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23413329 | 0.82 | GAA (0.60) | SCN2ASCN10ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL30097611 | 0.82 | GAA (0.60) | SCN2ASCN10ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL1134481 | 0.82 | SCN2A (0.64) | SCN2ASCN10ASMN1; SMN2CSF1RRET | |
| SCHEMBL259290 | 0.79 | RAB9A (0.69) | SCN2ASCN10ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3104769 | 0.76 | SCN2A (0.57) | SCN2ASCN10ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL259296 | 0.75 | KMT2A (0.80) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL30184168 | 0.75 | GAA (0.55) | SCN2ASCN10ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL25218898 | 0.75 | GAA (0.55) | SCN2ASCN10ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL259371 | 0.75 | KMT2A (0.66) | SMN1; SMN2MEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2700639-A1 | Selective ligands for the neuronal nicotinic receptors and uses thereof | Abbvie Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8648084-B2 | Selective substituted pyrazine ligands for neuronal nicotinic receptors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120190692-A1 | SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
| US-8148408-B2 | Selective substituted pyridine ligands for neuronal nicotinic receptors | ABBOTT LABORATORIES (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | ABBOTT LABORATORIES (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190692-A1 | SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS | CHRNA4, CHRNB4, CHRNA2 | SCN2A 106/4885SCN10A 152/4885SMN1; SMN2 306/4885 |
| US-20090281118-A1 | Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof | CHRNA4, CHRNB4, CHRNA2 | SCN2A 113/4885SCN10A 139/4885SMN1; SMN2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.